Insiders

01-21 Gilead Sciences Insider Sold Shares Worth $617,500, According to a Recent SEC Filing MT
01-12 Kyverna Therapeutics, Inc. Appoints Christi Shaw as Executive Chairperson of the Board, Effective January 12, 2026 CI
01-05 Tango Therapeutics, Inc. Appoints Sung Lee to its Board of Directors CI
12-18 Cartesian Therapeutics, Inc. Announces the Appointment of Adrian Bot to Board of Directors and Member of the Science and Technology Committee CI
12-18 Gilead Sciences, Inc. Appoints Keeley Wettan as Executive Vice President, General Counsel, Legal & Compliance Effective December 18, 2025 CI
12-16 Pliant Therapeutics, Inc. Appoints Minnie Kuo as Chief Operating Officer, Effective December 10, 2025 CI
12-03 Soleno Therapeutics, Inc. Announces Demise of William G. Harris, Member of Board of Directors and Audit Committee Changes CI
11-26 Vera Therapeutics, Inc. Appoints James R. Meyers to Its Board of Directors CI
11-19 Gilead says Deborah Telman to step down as evp at Gilead Sciences - SEC filing RE
11-19 Deborah H. Telman to No Longer Serve as Executive Vice President, Corporate Affairs and General Counsel of Gilead Sciences, Inc. as of December 5, 2025 CI
11-19 Gilead Sciences Insider Sold Shares Worth $3,524,173, According to a Recent SEC Filing MT
11-14 Cytokinetics, Incorporated Appoints Jeffrey J. Hessekiel as Executive Vice President, Chief Legal and Administrative Officer, Effective as of November 14, 2025 CI
11-14 Gilead Sciences Insider Sold Shares Worth $6,590,487, According to a Recent SEC Filing MT
11-10 Nurix Therapeutics, Inc. Appoints Roger Dansey to Its Board of Directors CI
11-07 Immuthera and Its Wholly Owned Subsidiary of Poltreg S.A Appoints Adrian Bot to Its Board of Directors CI
11-03 Prime Medicine, Inc. Appoints Matthew Hawryluk as Chief Business Officer CI
25-10-31 Galapagos NV Announces Board Changes, Effective November 1, 2025 CI
25-10-29 Gilead Sciences Insider Sold Shares Worth $1,193,926, According to a Recent SEC Filing MT
25-10-28 Jazz Pharmaceuticals plc Announces Board Changes, Effective December 1, 2025 CI
25-09-30 Gilead Sciences Insider Sold Shares Worth $1,116,564, According to a Recent SEC Filing MT
25-09-16 Gilead Sciences Insider Sold Shares Worth $340,710, According to a Recent SEC Filing MT
25-09-16 Gilead Sciences Insider Sold Shares Worth $283,925, According to a Recent SEC Filing MT
25-08-29 Gilead Sciences Insider Sold Shares Worth $1,136,300, According to a Recent SEC Filing MT
25-08-19 Gilead Sciences Insider Sold Shares Worth $3,318,927, According to a Recent SEC Filing MT
25-08-14 Gilead Sciences, Inc. Announces Management Changes, Effective September 22, 2025 CI
No results for this search